These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

112 related items for PubMed ID: 20534288

  • 21. Improvement of renal function after the switch from a calcineurin inhibitor to everolimus in liver transplant recipients with chronic renal dysfunction.
    Castroagudín JF, Molina E, Romero R, Otero E, Tomé S, Varo E.
    Liver Transpl; 2009 Dec; 15(12):1792-7. PubMed ID: 19938140
    [Abstract] [Full Text] [Related]

  • 22. Comparison of the safety and efficacy of cyclosporine minimization versus cyclosporine elimination in de novo renal allograft patients receiving sirolimus.
    Tedesco-Silva H, Garcia VD, Contieri FL, De Boni Monteiro de Carvalho D, Noronha IL, Gonçalves RT, de Paula FJ, Abbud-Filho M, Manfro RC, David-Neto E, Alfieri F, Ikehara E, Jiang Q, Tai SS, Medina-Pestana JO.
    Transplant Proc; 2010 Jun; 42(5):1659-66. PubMed ID: 20620495
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Once daily tacrolimus formulation: monitoring of plasma levels, graft function, and cardiovascular risk factors.
    Meçule A, Poli L, Nofroni I, Bachetoni A, Tinti F, Umbro I, Barile M, Berloco PB, Mitterhofer AP.
    Transplant Proc; 2010 May; 42(4):1317-9. PubMed ID: 20534290
    [Abstract] [Full Text] [Related]

  • 25. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients.
    Tedesco-Silva H, Vitko S, Pascual J, Eris J, Magee JC, Whelchel J, Civati G, Campbell S, Alves-Filho G, Bourbigot B, Garcia VD, Leone J, Esmeraldo R, Rigotti P, Cambi V, Haas T, 2306 and 2307 study groups.
    Transpl Int; 2007 Jan; 20(1):27-36. PubMed ID: 17181650
    [Abstract] [Full Text] [Related]

  • 26. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 27. Everolimus in clinical practice--renal transplantation.
    Pascual J.
    Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii18-23. PubMed ID: 16815852
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 30. Interaction between everolimus and tacrolimus in renal transplant recipients: a pharmacokinetic controlled trial.
    Pascual J, del Castillo D, Cabello M, Pallardó L, Grinyó JM, Fernández AM, Brunet M.
    Transplantation; 2010 Apr 27; 89(8):994-1000. PubMed ID: 20335831
    [Abstract] [Full Text] [Related]

  • 31. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 32. Late conversion from calcineurin inhibitor-based to sirolimus-based immunosuppression due to chronic toxicity: a prospective study with protocol biopsy amendment.
    Uslu A, Töz H, Sen S, Alkan FT, Nart A, Aykas A, Doğan M, Postaci H, Sahin T, Simşek C.
    Transplant Proc; 2009 Mar 15; 41(2):756-63. PubMed ID: 19328973
    [Abstract] [Full Text] [Related]

  • 33. Everolimus in pediatric de nova renal transplant patients.
    Hoyer PF, Ettenger R, Kovarik JM, Webb NJ, Lemire J, Mentser M, Mahan J, Loirat C, Niaudet P, VanDamme-Lombaerts R, Offner G, Wehr S, Moeller V, Mayer H, Everolimus Pediatric Study Group.
    Transplantation; 2003 Jun 27; 75(12):2082-5. PubMed ID: 12829916
    [Abstract] [Full Text] [Related]

  • 34. Effect of early cyclosporine levels on kidney allograft rejection.
    Johnson EM, Canafax DM, Gillingham KJ, Humar A, Pandian K, Kerr SR, Najarian JS, Matas AJ.
    Clin Transplant; 1997 Dec 27; 11(6):552-7. PubMed ID: 9408683
    [Abstract] [Full Text] [Related]

  • 35. Everolimus with reduced calcineurin inhibitor in thoracic transplant recipients with renal dysfunction: a multicenter, randomized trial.
    Gullestad L, Iversen M, Mortensen SA, Eiskjaer H, Riise GC, Mared L, Bjørtuft O, Ekmehag B, Jansson K, Simonsen S, Gude E, Rundqvist B, Fagertun HE, Solbu D, Bergh CH.
    Transplantation; 2010 Apr 15; 89(7):864-72. PubMed ID: 20061999
    [Abstract] [Full Text] [Related]

  • 36. Minimization of maintenance immunosuppression early after renal transplantation: an interim analysis.
    Bemelman FJ, de Maar EF, Press RR, van Kan HJ, ten Berge IJ, Homan van der Heide JJ, de Fijter HW.
    Transplantation; 2009 Aug 15; 88(3):421-8. PubMed ID: 19667948
    [Abstract] [Full Text] [Related]

  • 37. Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients.
    Budde K, Neumayer HH, Lehne G, Winkler M, Hauser IA, Lison A, Fritsche L, Soulillou JP, Fauchald P, Dantal J, RADW 102 Renal Transplant Study Group.
    Nephrol Dial Transplant; 2004 Oct 15; 19(10):2606-14. PubMed ID: 15316094
    [Abstract] [Full Text] [Related]

  • 38. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial.
    De Simone P, Metselaar HJ, Fischer L, Dumortier J, Boudjema K, Hardwigsen J, Rostaing L, De Carlis L, Saliba F, Nevens F.
    Liver Transpl; 2009 Oct 15; 15(10):1262-9. PubMed ID: 19790150
    [Abstract] [Full Text] [Related]

  • 39. Everolimus in pulmonary transplantation: pharmacokinetics and exposure-response relationships.
    Kovarik JM, Snell GI, Valentine V, Aris R, Chan CK, Schmidli H, Pirron U.
    J Heart Lung Transplant; 2006 Apr 15; 25(4):440-6. PubMed ID: 16563975
    [Abstract] [Full Text] [Related]

  • 40. Cyclosporine and sirolimus pharmacokinetics and drug-to-drug interactions in kidney transplant recipients.
    Felipe CR, Park SI, Pinheiro-Machado PG, Garcia R, Casarini DE, Moreira S, Tedesco-Silva H, Medina-Pestana JO.
    Fundam Clin Pharmacol; 2009 Oct 15; 23(5):625-31. PubMed ID: 19656203
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.